{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:58:24Z","timestamp":1791305904824,"version":"4.3.1"},"reference-count":19,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":571,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2000,6]]},"abstract":"<jats:p> <jats:bold>\n            <jats:italic>Aims<\/jats:italic>\n          <\/jats:bold>\u2002In October 1995 in response to the results of three studies, the Committee on the Safety of Medicines advised doctors and pharmacists that oral contraceptives containing desogestrel (DSG) and gestodene (GST) were associated with around a two\u2010fold increase in the risk of thromboembolism compared with those containing other progestogens. The objective of this study was to estimate the risk of idiopathic venous thromboembolic disease (VTE) in users of combined oral contraceptives (COCs), to compare the risk between formulations and to examine the effect of using age banding as opposed to matching by exact year of birth.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Methods<\/jats:italic>\n          <\/jats:bold>\u2002A nested case control study was conducted using the General Practice Research Database. Women with a VTE event recorded between 1992 and 1997, who were treated with an anticoagulant, from consideration of their prescription records were likely to have been using a COC prescription on the day of the event and also had no exclusion factors, were deemed cases. For comparison with the previous studies, two nested case control studies were undertaken. Study 1 used controls matched by practice and year of birth. Study 2 used controls matched by practice and within 5\u2003years age bands.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Results<\/jats:italic>\n          <\/jats:bold>\u2002We found an incidence of idiopathic VTE amongst users of combined oral contraceptives of 3.8 per 10\u2003000 exposed women years. Incidence rates increased markedly after 35\u2003years of age. The nested case\u2010control study using controls matched by year of birth showed no significant difference in risk between the major COC formulations. With levonorgestrel (LNG) 150\u2003\u00b5g and ethinyloestradiol (EE) 30\u2003\u00b5g as the reference, the adjusted ORs for GST 75\u2003\u00b5g and EE 30\u2003\u00b5g was 1.3 (95% CI 0.8, 2.1), for DSG 150\u2003\u00b5g and EE 30\u2003\u00b5g it was 1.0 (95% CI 0.7, 1.7) and for DSG 150\u2003\u00b5g and EE 20\u2003\u00b5g it was 0.8 (95% CI 0.4, 1.6). Using less rigorous matching criteria, matching controls to cases within 5\u2003years age bands, the ORs increased. When a mixed group of COCs, characterized by having LNG as the progestogen component was used as the reference category, there was an elevation in the ORs for the newer products. We found a significant association between idiopathic VTE and current smoking (OR 2.0 (1.4, 2.7)), BMI over 35 (OR 3.8 (1.8, 8.0)) and asthma (OR 1.9 (1.3, 2.9)). The OR for women who had proxy evidence of general ill health (indicated by the number of prescriptions issued) was 2.2 (1.7, 3.7).<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Conclusions<\/jats:italic>\n          <\/jats:bold>\u2002The results of this study indicate that a number of the characteristics of the women taking COCs affect the risk of VTE. There is no evidence to support the hypothesis that there is any difference in risk between COC formulations containing under 50\u2003\u00b5g ethinyloestradiol.<\/jats:p>","DOI":"10.1046\/j.1365-2125.2000.00198.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T04:38:28Z","timestamp":1047357508000},"page":"580-590","source":"Crossref","is-referenced-by-count":96,"title":["A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives"],"prefix":"10.1111","volume":"49","author":[{"given":"R. D. T.","family":"Farmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A.","family":"Lawrenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u2010C.","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. J.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. D.","family":"MacRae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Tyrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. M.","family":"Leydon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"Committee on the Safety of Medicines. Combined oral contraceptives and thromboembolism. London Committee on the Safety of Medicines 1995."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91928-7"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","unstructured":"SpitzerWO LewisMA HeinemannLA ThorogoodM MacRaeKD.Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case\u2010control study. Transnational Research Group on Oral Contraceptives and the Health of Young WomenBr Med J1996;312:8388.","DOI":"10.1136\/bmj.312.7023.83"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91927-9"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(96)00112-6"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115799"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.292.6519.526"},{"key":"e_1_2_6_9_2","first-page":"91","article-title":"Venous thromboembolism in relation to oral contraceptive use","volume":"69","author":"Helmrich SP","year":"1987","journal-title":"Obstet Gynecol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7013.1111"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/377663a0"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91921-X"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07496-X"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.302.6779.766"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2630030106"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a112646"},{"key":"e_1_2_6_17_2","first-page":"299","article-title":"Oral contraceptives and nonfatal vascular disease \u2013 Recent experience","volume":"59","author":"Porter JB","year":"1982","journal-title":"Obstetrics Gynaecol"},{"key":"e_1_2_6_18_2","first-page":"1","article-title":"Oral contraceptives and nonfatal vascular disease","volume":"66","author":"Porter JB","year":"1985","journal-title":"Obstetrics Gynaecol"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/19.4.931"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)60173-0"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2000.00198.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2000.00198.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.2000.00198.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T09:20:20Z","timestamp":1698571220000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.2000.00198.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,6]]}},"alternative-id":["10.1046\/j.1365-2125.2000.00198.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00198.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,6]]}}}